Fournier‘s gangrene and gliflozins in therapy of diabetes mellitus
Authors:
J. Brož 1; J. Urbanová 2; L. Brunerová 2
Authors‘ workplace:
Interní klinika FN Motol a 2. LF UK, Praha, přednosta prof. MUDr. M. Kvapil, CSc., MBA
1; Centrum pro výzkum diabetu, metabolismu a výživy, II. interní klinika 3. LF UK a FNKV, Praha, přednosta prof. MUDr. M. Kršek, CSc.
2
Published in:
Ceska Gynekol 2019; 84(1): 77
Category:
Letters to the Editor
Sources
1. Lupsa, BC., Inzucchi, SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia, 2018, 61, p. 2118–2125. doi:10.1007/s00125-018-4663-6.
2. Sorensen, MD., Krieger, JN. Fournier‘s gangrene: epidemiology and outcomes in the general US population. Urol Int, 2016, 97(3), p. 249–259.
3. Šuráň, M., Jarošincová, J., Milota, J. Fournierova gangréna. Urol praxi, 2017, 18(3), p. 124–126.
4. The Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm [Accessed 01.12.2018].
5. Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med, 2013, 159, p. 262–274.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2019 Issue 1
Most read in this issue
- Endometriosis in pregnancy – diagnostics and management
- Diagnostics and modern trends in therapy of postpartum depression
- Cervical cerclage – history and contemporary use
- Uterine microbiome and endometrial receptivity